STOCK TITAN

bvxv - bvxv STOCK NEWS

Welcome to our dedicated news page for bvxv (Ticker: bvxv), a resource for investors and traders seeking the latest updates and insights on bvxv.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect bvxv's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of bvxv's position in the market.

Rhea-AI Summary
Scinai Immunotherapeutics announces Chief Science Officer and University Medical Center Göttingen's Director to present at the 5th Dermatology Drug Development Summit Europe on the use of NanoAbs for plaque psoriasis treatment. Scinai's Anti-IL-17A/F NanoAbs show promising results in preclinical studies and are expected to address unmet needs in psoriasis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
Rhea-AI Summary
Scinai Immunotherapeutics Ltd. (SCNI) will be showcasing its cGMP biologics CDMO services and innovative NanoAb pipeline at the BIO-Europe Spring 2024 conference in Barcelona. The company aims to attract prospective clients for its CDMO services, pharma partners for its NanoAb in dermatology, and investors interested in SCNI's value proposition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
conferences
-
Rhea-AI Summary
Scinai Immunotherapeutics Ltd. announces the appointment of Liat Halpert as Head of Business Development and Sales, aiming to expand its CDMO services and advance its NanoAb therapeutics pipeline for I&I diseases. Halpert brings vast pharmaceutical sales and marketing experience from Novartis, targeting European and US-based biotech companies for growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
Rhea-AI Summary
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced the closing of its exercise of outstanding warrants, resulting in approximately $1.69 million in gross proceeds. The company intends to utilize the net proceeds for general working capital, research and development, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.84%
Tags
none
-
Rhea-AI Summary
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) has regained compliance with Nasdaq listing rules regarding minimum stockholders' equity. The company received formal notification from Nasdaq based on its Form 6-K dated November 13, 2023. The notification is related to a revised financial facility contract with the European Investment Bank, a change in the company's functional currency from NIS to USD, and an updated assessment of Scinai's weighted average cost of capital (WACC) to 35%. Additionally, the company received a letter regarding non-compliance with the minimum bid price requirement, which it intends to address.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
bvxv

Nasdaq:BVXV

BVXV Rankings

BVXV Stock Data

4.97M
2.72M
20.02%
10.69%
0.13%